Arolt C, Dugan M, Wild R, Richartz V, et al. KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer. J Thorac Oncol 2023 Jul 18:S1556-0864(23)00684.
PMID: 37473958